课题基金 / 基金详情

I-DOMAIN CONTAINING INTEGRIN/LIGAND INTERACTIONS

I-DOMAIN CONTAINING INTEGRIN/LIGAND INTERACTIONS
含有整合素/配体相互作用的 I 结构域
批准号:
6490063
负责人:
YOSHIKAZU TAKADA
金额:
$30.51万
依托单位国家:
美国
项目类别:
财政年份:
1995
资助国家:
美国
项目状态:
已结题
起止时间:
1995-01-01 至 2003-12-31

项目摘要

项目成果

YOSHIKAZU TAKADA的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Integrin/ligand interaction is involved in the pathogenesis of many diseases and, therefore, is a therapeutic target. Significant findings in the field of integrin studies have been recently published, including: 1) The crystal structure of the I domain; 2) A Beta-propeller model of the alpha subunit N-terminus; 3) An I-domain-like structure in the Beta subunit; and 4) A model of integrin activation. Our discoveries during the current project period include: 1) Ligand binding sites in the I domain; 2) Residues in the proposed Beta-propeller domain that are critical for ligand binding; 3) Residues that determine ligand specificity in Beta subunits; and 4) multiple conformation-dependent epitopes in the Beta subunit. These findings complement the crystal structure of the alpha I domain, and substantiate the proposed models. Based on progress during the current project period, we propose to study: 1) the role of the proposed Beta-propeller domain in I domain/ligand interaction; 2) the role of the diverse region in the Beta2 subunit that determines ligand specificity; 3) the binding sites in Beta2 integrins for ligand-derived binding motifs in I-domain integrins; and 4) the role of cation binding in I domain/ligand interaction. The proposed studies will lead to an increase in our understanding of integrin structure, regulation, and ligand interactions. These studies could potentially lead to the design of inhibitors or activators that could be useful for preventing cancer metastasis, rejection of a transplanted organ, or other medical conditions.
期刊论文(24)
专著(0)
科研奖励(0)
会议论文
Critical threonine and aspartic acid residues within the I domains of beta 2 integrins for interactions with intercellular adhesion molecule 1 (ICAM-1) and C3bi.
β2 整联蛋白 I 结构域内的关键苏氨酸和天冬氨酸残基与细胞间粘附分子 1 (ICAM-1) 和 C3bi 相互作用。
DOI: 10.1074/jbc.270.21.12531
发表时间: 1995
期刊: The Journal of biological chemistry
影响因子: --
作者: [Kamata,T, Wright,R, Takada,Y]
通讯作者: Takada,Y
A novel monoclonal antibody recognizing a cation-dependent epitope within the regulatory loop of human beta(1) integrin (CD29).
一种新型单克隆抗体,可识别人 β(1) 整合素 (CD29) 调节环内的阳离子依赖性表位。
DOI: 10.1089/153685902760213868
发表时间: 2002
期刊: Hybridoma and hybridomics
影响因子: --
作者: [Lévesque,Jean-Pierre, Takada,Yoshikazu, Puzon-McLaughlin,Wilma, Simmons,PaulJ]
通讯作者: Simmons,PaulJ
Specific interaction of the recombinant disintegrin-like domain of MDC-15 (metargidin, ADAM-15) with integrin alphavbeta3.
MDC-15(metargidin,ADAM-15)的重组解整合素样结构域与整合素 alphavbeta3 的特异性相互作用。
DOI: 10.1074/jbc.273.13.7345
发表时间: 1998
期刊: The Journal of biological chemistry
影响因子: --
作者: [Zhang,XP, Kamata,T, Yokoyama,K, Puzon-McLaughlin,W, Takada,Y]
通讯作者: Takada,Y
Critical residues for ligand binding in an I domain-like structure of the integrin beta1 subunit.
整合素 beta1 亚基的 I 结构域样结构中配体结合的关键残基。
DOI: 10.1074/jbc.271.34.20438
发表时间: 1996
期刊: The Journal of biological chemistry
影响因子: --
作者: [Puzon-McLaughlin,W, Takada,Y]
通讯作者: Takada,Y
POTENTIAL OF NOVEL ANTI-INFLAMMATORY AGENTS TO SUPPRESS CHRONIC INFLAMMATION
POTENTIAL OF NOVEL ANTI-INFLAMMATORY AGENTS TO SUPPRESS CHRONIC INFLAMMATION
Potential of a dominant-negative FGF mutant as a therapeutic in cancer
  • 批准号:
    7653318
  • 项目类别:
  • 资助金额:
    $31.68万
  • 财政年份:
    2009
  • 负责人:
    YOSHIKAZU TAKADA
  • 依托单位:
Potential of a dominant-negative FGF mutant as a therapeutic in cancer
  • 批准号:
    8015202
  • 项目类别:
  • 资助金额:
    $30.84万
  • 财政年份:
    2009
  • 负责人:
    YOSHIKAZU TAKADA
  • 依托单位:
海外基金